12/11/2025
Despite funding pressures in biotech and pharma, Avant Bio’s Daniella Kranjac sees major innovation ahead. Ahead of the Global Fund Women Conference, she spoke with us about:
🔬 Avant Bio’s strategy in techbio and therapeutic-enabling technologies
⚙️ How the firm accelerates growth for revenue-generating life sciences companies
🤖 AI-driven platforms like Intrepid Labs tackling the $400B pharma patent cliff
🌐 Why the convergence of biology + technology signals a new “golden age”
Read the full interview here: https://hedgefundalpha.com/profile/daniella-kranjac-avant-bio-interview/
Avant Bio’s Daniella Kranjac shares her growth equity strategy, value-add model, and why she sees a new golden age emerging in life sciences.